ReviewJournal of pain research2014
Tackling chronic migraine: current perspectives.
Review in Journal of pain research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Pharmacological agents for the prevention of vestibular migraine.The Cochrane database of systematic reviews · 2015Pooled it
- Occipital nerve stimulation for chronic migraine--a systematic review and meta-analysis.PloS one · 2015Pooled it
- Migraine incidence in 5 years: a population-based prospective longitudinal study in Turkey.The journal of headache and pain · 2015Trial
- Cerebrovascular reactivity after functional activation of the Brain using Photic Stimulation in Migraine and Tension Type Headache: a transcranial doppler Ultrasonography Study.BMC neurology · 2023Article
- Levels and determinants of knowledge about chronic migraine diagnosis and management among primary health-care physicians in ministry of health, Jeddah 2019.Journal of family medicine and primary care · 2020Article
- Conditions Associated with Essential Tremor in Veterans: A Potential Role for Chronic Stress.Tremor and other hyperkinetic movements (New York, N.Y.) · 2018Article
- Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain.BMJ open · 2017Article
- The Insula: A "Hub of Activity" in Migraine.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2016Review
- Effectiveness and safety of an extended-release tablet of sodium valproate for the prophylactic treatment of migraine: Postmarketing surveillance in Japan.Neurology and clinical neuroscience · 2016Article
- Chronic Migraine in Children and Adolescents.Current pain and headache reports · 2016Article
- Outcome of Chronic Daily Headache or Chronic Migraine.Current pain and headache reports · 2016Review
- Contribution of Piezo2 to endothelium-dependent pain.Molecular pain · 2015Article
- Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety.Toxins · 2015Review
- Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study.The journal of headache and pain · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, several diagnostic criteria and definitions have been proposed for chronic migraine (CM). The third edition of the International Classification of Headache Disorders-3 beta, published in 2013, has revised CM diagnostic criteria. CM is defined as "headache occurring on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month." Patients who meet the criteria for CM and for medication-overuse headache should be given both diagnoses. Worldwide, CM prevalence ranges 1%-3%, and its incidence has been estimated to be 2.5% per year. CM is associated with disability and poor quality of life. Modifiable risk factors include (among others): migraine progression (defined as an increase in frequency and severity of migraine attacks); medication and caffeine overuse; obesity; stressful life events; and snoring. CM patients have a significantly higher frequency of some comorbid conditions, including chronic pain, psychiatric disorders, respiratory illness, and some vascular risk factors. Management includes identification and control of comorbidities and risk factors that predispose to CM; treatment and prevention for medication overuse; early treatment for migraine attacks; and an adequate preventive therapy for CM. Several randomized controlled clinical trials have shown the efficacy of topiramate, amitriptyline, onabotulinumtoxinA, and cognitive-behavioral therapy in CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.